Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte priced an equity-and-debt financing comprising 7,412,500 common shares, 400,000 pre-funded warrants and $500 million of 1.50% convertible notes due 2032. The deal brings substantial capital to its vaccine pipeline while creating near-term dilution and future conversion exposure.
STOCK PHOTO · PIXABAYThe story
Vaxcyte said on Oct. 6 that it had priced concurrent underwritten offerings of 7,412,500 common shares, pre-funded warrants for 400,000 shares and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032. The common stock is priced at $64 per share, while the pre-funded warrants are priced at $63.999 each.
The financing combines immediate equity issuance with long-dated convertible debt. The notes carry a 1.50% coupon and mature in 2032, giving Vaxcyte access to capital at a stated interest cost while preserving a potential future share-conversion obligation.
The proceeds are tied to a clinical-stage vaccine developer whose value depends on advancing its development programs and ultimately commercializing a product. The stock offering increases the number of shares outstanding immediately, and the pre-funded warrants add another potential source of share issuance.
The longer-term outcome depends on how effectively Vaxcyte converts the financing into clinical and regulatory progress. The financing terms establish the capital structure, but they do not by themselves establish an approval timeline or commercial revenue outcome.
The next evidence points are Vaxcyte’s subsequent filings on the offering and the company’s next clinical or corporate update, including how it describes the use of proceeds and the progress of its vaccine programs.
Our read · Tue, Oct 6
PCVX priced 7,412,500 shares, 400,000 pre-funded warrants and $500 million of convertible notes due 2032.
Why. The financing materially extends Vaxcyte’s capital base, but the immediate equity issuance and potential warrant and note conversion create dilution alongside that funding. The read remains balanced because the terms provide resources for a clinical-stage pipeline without establishing a near-term clinical or regulatory outcome.
Both cases
What could change this view: A weak clinical update or slower-than-expected development progress could leave the new capital unable to support the valuation implied by the financing.
Who reported it · 1
Keep reading
More on PCVX
Vaxcyte sets October 5 readout for pivotal VAX-31 vaccine trialLatest on the Wire
Iran claims strikes on two US bases in Bahrain as Trump line is testedTrump calls Russian missiles in Poland mistakes before fresh incursionAmazon nears $7.5bn Decart deal as AWS takes on Nvidia in AI computingRussian cargo ship Sparta II reportedly hit by drones near FinlandBTCS warns $54 million Aave loan faces liquidation as ether fallsContinue on the Wire →Latest on the Wire
BTCS warns $54 million Aave loan faces liquidation as ether fallsIntesa Sanpaolo launches €34.5bn cash-and-share offer for Monte dei PaschiIran war sees tanker hit near Hormuz as Saudi Arabia intercepts Houthi missilesNvidia tumbles as US tech stocks enter bear market on AI spending fearsContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →